Related Experiment Video
Updated: May 1, 2026

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart
Published on: January 7, 2019
Stem cell therapy for cardiovascular disorders - our clinical experience
A G Jayakrishnan1, N Madhusankar2, Y Y Rao3
1Omega Hospital , Mangalore, India ; Fr. Mullers Hospital , Mangalore, India.
Insights
Autologous bone marrow stem cell therapy shows promise for end-stage heart failure patients. This treatment improved cardiac function and quality of life in a small patient group.
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Limited treatment options exist for end-stage heart failure due to cardiomyopathy.
- Autologous bone marrow stem cells offer a potential therapeutic approach.
- Stem cells may replace damaged cells, stimulate local growth via paracrine effects, and recruit other stem cells.
Purpose of the Study:
- To evaluate the efficacy of autologous bone marrow-derived stem cells in patients with end-stage heart failure.
- To assess functional improvement and quality of life following stem cell transplantation.
Main Methods:
- A study involving 13 patients with cardiomyopathy (ischemic dysfunction, dilated cardiomyopathy, pulmonary hypertension).
- Patients received isolated and expanded CD34+ cells from bone marrow.
- Stem cells were administered via intracoronary injection, direct myocardial injection, or intrapulmonary delivery.
Main Results:
- All patients demonstrated functional improvement in myocardial function.
- Non-invasive investigations confirmed enhanced cardiac function.
- Patients reported an improved quality of life.
- Follow-up ranged from 6 months to 2 years.
Conclusions:
- Bone marrow-derived stem cells show encouraging results in treating cardiomyopathy.
- Further studies are warranted to confirm these findings and explore long-term outcomes.
Background:
Autologous Bone Marrow stem Cell transplantation is a viable therapeutic option for patients with end stage heart failure due to cardiomyopathy of varied etiology as there are only limited treatment options other than cardiac transplantation. The rationale behind the application of stem cells in these patients include Stem cells directly replace the affected cells by differentiation into the damaged cell typeStem cells also exert Paracrine effects by secretion of growth factors (VGEF,FGF-1)to stimulate local cell growthIn addition to the above, stem cells release signaling factors which recruit stem cells from elsewhere by modulating the immune system.
Materials & Methods:
In this presentation we describe our study on a series of 13 patients who received isolated and expanded CD 34 cells from the bone marrow. Seven had ischemic dysfunction, three had dilated cardiomyopathy and three had primary pulmonary hypertension. Five patients received the stem cells via intracoronary injection, three directly into the myocardium and three intrapulmonary.
Results:
All patients showed functional improvement of the myocardium recorded by non-invasive investigations and improvement in the quality of life. Follow up period ranged from 6 months to 2 years.
Conclusion:
Our experience with bone marrow derived stem cells in patients with cardiomyopathy has been encouraging. More studies are planned in the future.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Clinical Applications of Epidermal Stem Cells
Stem Cell Culture
Adult Stem Cells

